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SUMMARY
Pseudomyxoma peritonei (PMP) is a subtype of mucinous adenocarcinoma that most often originates from the appendix, and grows in the peritoneal cavity filling it with mucinous ascites. KRAS and GNAS mutations are frequently found in PMP, but other common driver mutations are infrequent. As altered glycosylation can promote carcinogenesis, we compared N-linked glycan profiles of PMP tissues to those of normal appendix. Glycan profiles of eight normal appendix samples and eight lowgrade and eight high-grade PMP specimens were analyzed by mass spectrometry. Our results show differences in glycan profiles between PMP and the controls, especially in those of neutral glycans, and the most prominent alteration was increased fucosylation. We further demonstrate up-regulated mRNA expression of four fucosylation-related enzymes, the core fucosylation performing fucosyltransferase 8 and three GDP-fucose biosynthetic enzymes in PMP tissues when compared to the controls. Up-regulated protein expression of the latter three enzymes was further observed in PMP cells by immunohistochemistry. We also demonstrate that restoration of fucosylation either by salvage pathway or by introduction of an expression of intact GDP-mannose 4,6-dehydratase enhance expression of MUC2, which is the predominant mucin molecule secreted by the PMP cells, in an intestinal-derived adenocarcinoma cell line with defective fucosylation due to deletion in the GDPmannose 4,6-dehydratase gene. Thus, altered glycosylation especially in the form of fucosylation is linked to the characteristic mucin production of PMP. Glycomic data are available via ProteomeXchange with identifier PXD010086.
INTRODUCTION
Pseudomyxoma peritonei (PMP) is a rare mucinous adenocarcinoma with an incidence of one to two cases per million per year (1) . PMP originates most commonly from a low-grade appendiceal mucinous neoplasm (LAMN), and through its rupture neoplastic cells spread into the peritoneal cavity.
In the peritoneal cavity PMP cells grow relatively slowly, but they secrete abundant amounts of extracellular mucin, which in the terminal phase of the disease causes progressive obstruction of the bowel that finally leads to death of the patient. PMP is classified into low-grade (LG) and high-grade (HG) subtypes (2, 3) , the five-year survival being 63% for the LG and only 23% for the HG disease (4) . The current standard treatment for PMP is aggressive cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (5) . However, this treatment is amenable only for 60-70% of the patients (6, 7) and a significant proportion of treated PMP patients get relapse (8) . Thus, biomarkers for estimation of the aggressiveness of the disease and novel targeted treatments are needed. Further, therapeutic interventions that would reduce secretion of mucinous ascites could potentially be beneficial for the patients.
We and others have previously shown that PMP contains activating mutations of KRAS (70-100%) and GNAS (38-69%) genes (9) (10) (11) (12) (13) (14) (15) (16) . We have also reported that several components of the cyclic AMPprotein kinase A pathway are mutated in PMP disease (16) , which stimulates mucin production (17, 18) . Glycosylation is an important post-translational modification of proteins, and all human cells have a glycan-rich coating composed of glycoproteins, glycolipids, and proteoglycans, which affect cell differentiation, adhesion, and proliferation (19) . In line with that, altered glycosylation has been observed in many types of malignant diseases (19) , and recently gastrointestinal cancers have been shown to express changes in asparagine-linked glycan (N-glycan) branching and increased fucosylation and sialylation (20) . Thus, glycomic profiling of neoplastic diseases has potential to reveal novel, effective molecular targets for diagnostics and as therapeutics.
In this study we characterize, for the first time, the N-linked glycan profiles of PMP by mass 5 spectrometry, and show differences in glycan profiles between the PMP tissue and normal appendix.
Further, we found differentially expressed glycosylation-related gene products, and analyzed expression of fucosylation-related enzymes and fucosylated glycans by immunohistochemistry and lectin histochemistry in the PMP tissue specimens. Finally, we confirmed the relationship between fucosylation and mucin expression in an intestinal-derived adenocarcinoma cell line.
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EXPERIMENTAL PROCEDURES
Experimental Design and Statistical Rationale
We utilized previously developed workflow (21) (22) (23) (24) to analyze the N-glycan profiles from formalinfixed, paraffin-embedded (FFPE) tissue specimens of PMP patients and normal control appendices.
For statistical comparisons we used eight control appendices and 16 PMP specimens, of which eight were LG PMPs and eight were HG PMPs. For analysis of glycosylation-related gene expression, we used previously published microarray data of 26 fresh frozen PMP specimens and three appendix controls (25) . The in vitro experiments were repeated at least three times, and in qPCR assays, three biological replicates and three to four technical replicates were used. The statistical analyses performed are detailed below in the corresponding chapters.
Tissue Specimens
For glycomic profiling, we selected FFPE tissue blocks from eight normal appendices, and eight LG and eight HG PMP specimens originating from the appendix. Detailed information of each specimen is listed in Supplemental Table S1 . The patients received no preoperative oncological treatments. To avoid fucosyltransferase 3 (FUT3) mutated cases, occurring in 5-10% of the population, only CA19-9 immunopositive cases were included based on our previous study (26) . All tissue specimens were routinely fixed and embedded in paraffin at the Department of Pathology, HUSLAB, Helsinki University Hospital, between 2007 and 2016, and the study was approved by the Ethics Committee of the Helsinki University Hospital. Areas containing the highest percentages of epithelial cells were first marked on HE slides and macrodissection was used to cut 30 μm thick flakes from the most representative areas, after which a new HE slide was stained to confirm the representativeness of the flakes. In addition, FFPE tissue specimens of appendix-derived PMPs (n = 100; 60 LG and 40 HG) and control appendices (n = 26) were used for immunohistochemistry and lectin histochemistry. For appendix the mean age is 57 and the median 60, range 31-80, and for PMP the mean age is 58 and the median 60, range 29-88; in respect of gender appendix group consisted of 58% females, the value for PMP being 60%. The appendiceal origin of the tumors was judged from the appendix tissue block 7 and/or the surgery report, and grading of the tumors was re-evaluated according to the WHO 2010 classification and the content of neoplastic cells in the tissue specimens was estimated by AR (2) . LG morphology was defined by strips of cells or small islands of relatively low cellularity with typically only low-grade atypia, whereas HG morphology contained more complex structures (invasive small cell clusters, cribriform structures and/or signet ring cell morphology), stromal reaction, and typically high-grade atypia with high cellularity. Any amount of HG morphology lead to classification of the tumor as HG PMP.
Glycan Isolation and Mass Spectrometry
FFPE tissue flakes were deparaffinized and disrupted in microcentrifuge tubes using a fitting plastic micro pestle, and N-linked glycans were detached by N-glycosidase F (PNGase F) digestion (Glyko; ProZyme Inc., Hayward, CA) and purified as previously reported (23) . Briefly, the detached glycans were passed in water through C18 silica and absorbed to graphitized carbon material, both in 96-well format. The carbon wells were washed with water, and neutral glycans were eluted with 25% acetonitrile and acidic glycans with 0.05% trifluoroacetic acid in 25% acetonitrile in water. The acidic glycans were further purified by hydrophilic interaction solid-phase extraction, also in 96-well format, after which both glycan fractions were additionally passed in water through strong cation-exchange Tables S2 and S3 ) (21, 22) .
Analysis of N-glycan Profiles
N-glycan data was analyzed in four different study group settings: control appendices, LG PMPs, HG PMPs, and all PMP samples. For statistical analyses, two-sided Wilcoxon Rank Sum test for the mean value of relative intensities of N-glycan signals was used to compare the differences between the groups. To visualize the differences between the groups, we used Principal component analysis (PCA).
It was first performed by using all glycan structures, but in this analysis the sample groups were not statistically significantly separated (result not shown). Next we performed the PCA using neutral and acidic compositions whose relative intensities differed significantly (p < 0.05) between the control appendices and all PMP samples, as well as between the LG PMPs and the HG PMPs. Two components were extracted, and Bartlett's and Kaiser-Meyer-Olkin tests were used to test the adequacy of PCA for the data. Both the normalized signal intensity data and the assigned biosynthetic groupings were used for the analyses. Analyses were done by Anduril2 workflow framework (manuscript under preparation) and R (27) .
Validation of N-glycan Structures
To validate the proposed molecular structures, non-reducing terminal glycan epitopes of neutral Nglycan fraction from a HG PMP sample were analyzed by digestion with specific exoglycosidase enzymes: α-mannosidase from Jack beans (Canavalia ensiformis; Sigma-Aldrich, St. Louis, MO), β-
N-acetylglucosaminidase from Streptococcus pneumoniae (recombinant in Escherichia coli;
Calbiochem, San Diego, CA), β-N-acetylhexosaminidase from Jack beans (Seikagaku, Tokyo, Japan), α1,2-fucosidase from Xanthomonas manihotis (New England Biolabs, Ipswich, MA), and α1,3/4-fucosidase from Prunus dulcis (expressed in Pichia pastoris; New England Biolabs). Enzyme specificity toward isomeric structures was controlled with defined purified oligosaccharides. Reactions were carried out by overnight digestion at 37°C in 50 mM sodium acetate buffer (pH 5.0). Digested glycan fractions were purified for analysis by solid-phase extraction with graphitized carbon, analyzed by MALDI-TOF mass spectrometry as described above, and interpreted as previously (21) . For further verification of glycan structures the N-glycans were permethylated (28) for MS/MS fragmentation analysis.
Analysis of Microarray Data
The microarray data of 26 fresh frozen PMP specimens (24 LG, 2 HG) and three appendix controls (25) were kindly provided by Prof. Edward A. Levine (Wake Forest University, North Carolina, USA), and the analysis was performed with the Anduril workflow framework (29) and R. The raw expression data were normalized using the RMA (30) were scored as negative, weak (+), moderate (++), or strong (+++). In case two staining intensities were detected, the one covering the largest area was selected as the overall score. For statistical analysis the scoring was divided to low (negative and weak) and high (moderate and strong)
immunopositivity. The scoring was performed by HL and PN, and discrepant scores were evaluated separately, after which consensus score was used for the statistical analysis with Fisher's exact test.
Lectin Histochemistry
Three-μm tissue sections of 28 PMP tumors (14 LG, 14 HG) and ten control appendices were stained with Aleuria aurantia lectin (AAL), that binds to fucosylated glycans with a preference to α1,6-linked core fucose residues attached by FUT8 enzyme (32) . The sections were first deparaffinized and rehydrated, after which they were heated in Tris-HCl buffer (pH 8.5) in a microwave oven for 4 x 5 min to unmask the glycans. Endogenous peroxidase activity was blocked using 0.3% (v/v) hydrogen peroxide in methanol for 30 min and non-specific binding was reduced by blocking with 3% (w/v) BSA in PBS for 1 h. Horseradish peroxidase (HRP)-conjugated AAL (Alpha Diagnostic International, San Antonio, TX) was then incubated at a dilution of 1:1000 for 1 h in a moist chamber. After washing with PBS, the signal was developed with 3,3'-diaminobenzidine (DAB) as the chromogen.
Finally, the slides were counterstained with hematoxylin, dehydrated in ascending ethanol series, and embedded in Mountex (Histolab Products AB, Gothenburg, Sweden).
Cell Culture
Parental intestinal-derived carcinoma cell line HCT116 and a HCT116 cell line bearing activating GNAS mutation (R201C/+; both from Horizon Discovery Ltd., Cambridge, UK) were cultured in Chalfont, UK). The membranes were blocked with 5% milk and immunoblotted using rabbit anti-GMDS antibody (Proteintech Group) and HRP-conjugated anti-rabbit secondary antibody (DAKO/Agilent, Santa Clara, CA), or blocked with 3% BSA and lectin blotted using the above mentioned HRP-conjugated AAL. To verify equal loading of each lane, the membranes were blotted with mouse anti-α-Tubulin antibody (Abcam) and HRP-conjugated anti-mouse secondary antibody (DAKO).
Quantitative Polymerase Chain Reaction (qPCR) of MUC2
Total RNA was extracted from the cell pellets using NucleoSpin® RNA kit (Macherey-Nagel GmbH IBM Corporation, Armonk, NY).
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RESULTS
Neutral N-linked Glycan Profiles
Neutral N-linked glycan profiles of PMP patient specimens were analyzed using mass spectrometry.
Glycomic profiling of normal appendix controls and LG and HG PMP samples (n = 8 in each group) are shown as relative abundancy of the fifty most prominent proposed monosaccharide compositions in Fig. 1 . When neutral and acidic N-linked glycan profiles were stratified by biosynthetic classification rules based on the amounts of hexose (H), N-acetylhexosamine (N), and deoxyhexose (F) residues in the proposed monosaccharide compositions, and shown as proportion of major glycan structural classes between the control tissues and the PMP samples, we found several fucosylationrelated glycan classes to be elevated in the PMP samples when compared to the controls (Table) . In order to validate the proposed monosaccharide compositions, a PMP sample was further analyzed 14 with a combination of MS/MS fragmentation analysis directed to specific glycan signals (Supplemental Fig. S2 ) and by exoglycosidase digestions of the glycan mixture (Supplemental Fig. S3 and Supplemental Table S5 ). As an example, glycan signal H3N4F1 was putatively classified as a complex-type N-glycan with terminal N-acetylhexosamine and fucosylation, since it contains at least four N-acetylhexosamine residues (N≥4), more N-acetylhexosamine than hexose residues (N≥H), and at least one deoxyhexose residue (F≥1), respectively. In MS/MS fragmentation analysis of a permethylated glycan sample (Supplemental Fig. S2A ), H3N4F1 produced characteristic fragments of two non-reducing terminal N-acetylhexosamine residues (m/z 1317 and 866) as well as N-glycan core fucosylation (m/z 474 for core fragment and 1384 for antenna fragment resulting from cleavage of the N-glycan core GlcNAc-GlcNAc linkage). The core fucose residue was shown to be α1,6-linked by the well-established specificity of the N-glycosidase F enzyme that was used to liberate the N-glycans from tissue (34) . A set of exoglycosidase digestions was used to further characterize the glycan structures in the N-glycan mixture (Supplemental Table S5 ). H3N4F1 was sensitive to both β-Nacetylglucosaminidase and β-N-acetylhexosaminidase enzyme digestions, which cleaved two terminal β-N-acetylglucosamine (β-GlcNAc) residues from the glycan converting the majority of the signal intensity to glycan signal H3N2F1 (Supplemental Fig. S3A and S3B ). In contrast, H3N4F1 was not sensitive to α-mannosidase, α1,2-fucosidase or α1,3/4-fucosidase digestions (Supplemental Table S5 ).
Taken together, these analyses confirmed the molecular structure of H3N4F1 as an α1,6-corefucosylated biantennary N-glycan with two non-reducing terminal β-GlcNAc residues. Similarly, glycan signal H5N4F3 was initially classified for complex fucosylation (multifucosylation), since it contained three deoxyhexose residues (F≥2). In MS/MS fragmentation analysis (Supplemental Fig.   S2B ), H5N4F3 produced fragments that were characteristic to both core fucosylation (m/z 717 and 1315) and antenna fucosylation (m/z 658 and 864). H5N4F3 was completely digested by α1,3/4-fucosidase digestion (Supplemental Fig. S3C ), but not by the other exoglycosidases, and it was only partially sensitive to α1,2-fucosidase (Supplemental Fig. S3D and Supplemental Table S5 Table S5 and data not shown). These data indicate that the proposed monosaccharide compositions could be validated as expected.
Acidic N-linked Glycan Profiles
Acidic N-linked glycan profiles, composed of glycans containing acid esters (sulfate or phosphate) or sialic acid residues, of the PMP patient specimens and the normal appendix controls are shown as relative abundancy of the fifty most prominent proposed monosaccharide compositions in Fig. 1B .
Similarly to the neutral glycans, complex fucosylation in hybrid-type (p = 0.046), terminal HexNAc (bisecting-size; p = 0.029), and complex-type structures (p = 0.007) were elevated in the acidic glycan profiles of PMP samples (Table) . The only structure which abundance was decreased in PMP in the acidic glycan group was the hybrid-type (p = 0.006). However, altered sialylation was not a prominent feature in PMP profiles (Supplemental Table S6 ).
Principal Component Analysis of Differentially Expressed N-Linked Glycans
To further visualize the difference between PMP patient specimens and the controls, we selected from both the neutral and acidic N-glycan profiles those glycan signals that were significantly different (p < 0.05) between the appendix controls and PMP samples, as well as between LG and HG PMPs (Supplemental Table S7 ). Relative intensity of these structures for each sample were then subjected to 3 ). Two HG samples containing only 10-20% proportion of HG morphology (the rest of the HG samples containing 50-100% of HG morphology) clustered into the group of LG samples.
Expression of Glycosylation-Related Enzymes
Expression of glycosylation-related genes was analyzed from appendiceal PMP tissue samples (n = 16 26 ) and compared to appendix control samples (n = 3) using DNA microarray (25) . From over 1,200
glycosylation-related genes studied, 30 genes were found to be differentially expressed in PMP samples, and from these we identified four fucosylation-related enzymes, i.e. fucosyltransferase 8 (FUT8) that performs α1,6-linked core fucosylation and three enzymes of the GDP-fucose de novo biosynthetic pathway (GMDS, GMPPA, and TSTA3), to be up-regulated in the PMP samples. A schematic representation of the pathway for these enzymes is shown in the Fig. 4 . Expression of FUT8 was increased 2.3-fold and for the three GDP-fucose biosynthetic enzymes 1.8-fold in the PMP sample group (p < 0.0001 for all). When these fucosylation-related enzymes FUT8 (n = 100), GMDS (n = 99), GMPPA (n = 95), and TSTA3 (n = 100) were studied at the protein level by immunohistochemistry, the expression was shown to localize to the PMP cells ( Fig. 5A-D) . FUT8 immunopositivity was high in 75% of LG and 78% of HG PMPs, and low in rest of the samples, but the staining was not significantly differing from normal appendiceal epithelium (p = 0.795). GMDS was high in 85% of
LG and 90% of HG PMPs, and low in rest of the samples. GMPPA was high in 52% of LG and 66%
of HG PMPs, and low in rest of the samples. TSTA3 was high in 47% of LG and 53% of HG PMPs, and low in rest of the samples. All these three proteins showed higher expression in PMP samples than in control appendix specimens (p = 0.018 for GMDS, p < 0.0001 for GMPPA, and p = 0.0002 for TSTA3). Thus, the majority of the PMP samples overexpressed these enzymes, but no significant differences were found between frequency of expression of these markers between LG and HG samples.
Expression of Fucosylated Glycans
Expression of core fucosylated glycans was found in PMP cells and in their secreted mucus as detected by AAL lectin histochemistry (n = 28 for PMP and n = 10 for appendix) (Fig. 5E ). To further investigate complex fucosylation of glycans, we immunostained sLe x from the PMP sample set (n = 100), and, similarly, the immunopositivity localized in both PMP cells and mucus (Fig. 5F ). sLe x staining was high in 92% of LG and 97% of HG PMPs, and low in rest of the samples, and it showed significant overexpression as compared to normal appendiceal epithelium (n = 25) (p < 0.0001). In addition, mucus lakes stained very strongly (Fig. 5F ). In contrast to the fucosylation-related enzymes, which showed expression in normal appendiceal epithelial cells, sLe x staining was mainly negative in these cells with only some positive areas detected in 20% of the specimens. Also PMP samples (n = 8) previously found to demonstrate negative or weak immunostaining of sialyl-Lewis a (sLe a , also known as CA19-9) due to mutation in the biosynthetic enzyme FUT3 (26), showed intense staining of sLe x (data not shown).
Effect of Fucosylation on MUC2 Expression
To study the possible relationship between fucosylation and mucin production, we utilized the intestine-derived cancer cell line HCT116, which has defective fucosylation due to deletion in the GDP-fucose biosynthetic enzyme GMDS coding gene (33) . To restore fucosylation in these cells through salvage pathway (Fig. 4) , we added L-fucose into the growth medium or to restore fucosylation through de novo pathway, in a separate experiment, we transfected the cells with a wildtype copy of the GMDS cDNA. Both interventions increased core fucosylation as demonstrated by AAL lectin blotting (transfectants shown in Fig. 6A ). In a previous study, activating GNAS mutation was shown to up-regulate expression of MUC2, the predominant mucin molecule secreted by PMP tumor cells, when introduced into HT29 colon cancer cells (18) . In HCT116 cell, we found GNAS mutation to cause a moderate upregulation of MUC2 expression, which was significantly enhanced after restoring fucosylation (Fig. 6B ).
DISCUSSION
We found altered N-linked glycan profiles in PMP tissue specimens when compared to appendix controls, and increased fucosylation was an especially prominent feature. In addition to overall fucosylation, complex fucosylation (multifucosylation) was increased in PMP samples. Previously, altered fucosylation has been associated with aggressiveness of colorectal cancer (35, 36) , which may depend on increased EGFR-mediated signaling (37) and modulation of adhesion molecule function (38, 39). In addition, core fucosylation was recently shown to drive melanoma metastasis by preventing the proteolytic cleavage of adhesion molecule L1CAM (40).
Next we studied fucosylation-related gene expression in PMP tissue specimens compared to control appendices using DNA microarray (25) . In line with glycan profiles, we found increased expression of the core fucosylation performing enzyme FUT8, as well as three enzymes needed in the biosynthesis of its donor substrate GDP-fucose. With immunohistochemistry we could demonstrate up-regulated protein expression of the GDP-fucose biosynthetic enzymes (GMDS, GMPPA, and TSTA3) in PMP cells as compared to normal appendiceal epithelium. Fucosylated glycans, in turn, were detected in both PMP cells and the mucus secreted by them as shown by AAL lectin and sLe x immunohistochemical staining. Of these glycans, sLe x was significantly overexpressed in PMP cells, being mostly negative in normal appendiceal epithelial cells. These data support fucosylation to be a prominent feature of the PMP disease. Supporting our data, FUT8 has previously been shown to be up-regulated in hepatocellular carcinoma (41) , and knock-down of this enzyme inhibits malignant behavior of lung cancer cells (42) . In addition, pancreatic intraductal papillary mucinous neoplasm (IPMN) that is closely related to PMP in respect of mutation profiling (43, 44) show elevated FUT8
and GMDS expression, and fucosylation (45, 46) .
The complex fucosylation containing glycan CA19-9 (sLe a ) is a widely used serum tumor marker.
However, CA19-9 cannot be used in patients whose FUT3 is mutated (47, 48) , since other FUT enzymes do not compensate for the lack of α1,4-fucosylation activity of this enzyme. In our previous 19 study, we demonstrated that 9% (8/92) of PMP cases showed impaired CA19-9 expression due to FUT3 mutation (26) . In our present study, we found that all these cases showed intense staining of sLe x , which can be synthesized by FUT 3-7 enzymes. Thus, overexpression of sLe x and lack of sLe a is most likely accounted by the fact that other FUT enzymes (FUT4-7) are able to compensate the deficient α1,3-fucosylation activity of mutated FUT3, whereas they do not compensate the deficient α1,4-fucosylation activity of this α1,3/4-fucosyltransferase (49). Importantly, sLe x measurement might help in monitoring of patients with CA19-9 negative tumors, as has been already proposed for pancreatic cancer (50) , and could be a useful tumor marker also in PMP.
Over 60% of PMPs contain an activating GNAS mutation (9) (10) (11) (12) (13) (14) (15) 18) , which has been demonstrated to result in constitutive activation of the membrane protein adenylyl cyclase and increased expression of extracellular mucins MUC2 and MUC5AC in colon cancer HT29 cell line (18) . In contrast to HT29 cells, we found only modest induction of MUC2 expression induced by mutated GNAS in HCT116 cells, which has been reported to have defective fucosylation due to deletion in the GMDS gene (33) .
To test the possible relationship between GNAS mutation-induced MUC2 expression and fucosylation, we restored fucosylation through GDP-fucose de novo or salvage pathway. According to these results, GNAS mutation induced significantly higher MUC2 expression in HCT116 cell after restoration of fucosylation. Since elevated fucosylation and GNAS mutation are frequently found in PMP, this could partially explain the high mucin production in PMP disease.
In addition to fucosylation, we detected an increase in individual structural features previously associated with carcinogenesis, such as terminal GlcNAc (e.g. H3N4F1) (21), bisecting GlcNAc (e.g. LG: low-grade; HG: high-grade; PMP: pseudomyxoma peritonei Fucosylation here is defined as structures containing ≥1 deoxyhexoses (F).
TABLES
Complex fucosylation is defined as structures containing ≥2 deoxyhexoses (multifucosylation). 
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